Allergy Therapeutics plc Preliminary Results for the year ended 30 June 2020 - Seite 2

^*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

Analyst briefing and webcast today

Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Communications and Market Development, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am BST.

Dial-in details are:

Webcast link: https://www.lsegissuerservices.com/spark/AllergyTherapeutics/events/6b ...

UK dial-in: [phone]
US dial-in: [phone]
Conference ID: 4299121

- ENDS -

For further information, please contact:

Allergy Therapeutics
[phone]
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer

Panmure Gordon
[phone]
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking

Consilium Strategic Communications
[phone]
Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser
[e-mail]

Stern Investor Relations, Inc.
[phone]
Christina Tartaglia
[e-mail]

Notes for editors:
About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.